172 related articles for article (PubMed ID: 12939207)
21. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Smith DG; Cerulli A; Frech FH
Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
23. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
24. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Krum H; Latini R; Maggioni AP; Anand I; Masson S; Carretta E; Ingrillì F; Pettinati G; Glazer R; Tognoni G; Cohn J
Int J Cardiol; 2007 Jun; 119(1):48-53. PubMed ID: 17049646
[TBL] [Abstract][Full Text] [Related]
25. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
Latif F; Tandon S; Obeleniene R; Hankins SR; Berlowitz MS; Ennezat PV; Le Jemtel TH
J Card Fail; 2001 Sep; 7(3):265-8. PubMed ID: 11561228
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
28. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.
Peters S; Götting B; Trümmel M; Rust H; Brattström A
J Invasive Cardiol; 2001 Feb; 13(2):93-7. PubMed ID: 11176015
[TBL] [Abstract][Full Text] [Related]
29. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Lesogor A; Cohn JN; Latini R; Tognoni G; Krum H; Massie B; Zalewski A; Kandra A; Hua TA; Gimpelewicz C
Eur J Heart Fail; 2013 Nov; 15(11):1236-44. PubMed ID: 23787721
[TBL] [Abstract][Full Text] [Related]
30. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
31. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
[TBL] [Abstract][Full Text] [Related]
32. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Staszewsky L; Wong M; Masson S; Barlera S; Carretta E; Maggioni AP; Anand IS; Cohn JN; Tognoni G; Latini R;
J Card Fail; 2007 Dec; 13(10):797-804. PubMed ID: 18068611
[TBL] [Abstract][Full Text] [Related]
33. Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Cohn JN
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S38-40. PubMed ID: 17199220
[TBL] [Abstract][Full Text] [Related]
34. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
35. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
[TBL] [Abstract][Full Text] [Related]
36. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
[TBL] [Abstract][Full Text] [Related]
37. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
39. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
[TBL] [Abstract][Full Text] [Related]
40. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
